Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin.

Int J Mol Sci · 2026 · PMC13163365 · PMID 42123630

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendp = 0.10so close (0.05 < p ≤ 0.1)

In CD33 high patients, there was a trend toward longer OS ( p = 0.23), EFS ( p = 0.10), and RFS ( p = 0.059) in carriers of the T allele, whilst in CD33 low patients, carriers of the T allele showed a trend toward shorter survival (OS: p = 0.10; EFS: p = 0.07; RFS: p = 0.09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.